1. Home
  2. AKA vs AGEN Comparison

AKA vs AGEN Comparison

Compare AKA & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo a.k.a. Brands Holding Corp.

AKA

a.k.a. Brands Holding Corp.

HOLD

Current Price

$10.34

Market Cap

113.4M

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$4.64

Market Cap

124.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKA
AGEN
Founded
2018
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
113.4M
124.4M
IPO Year
2021
1999

Fundamental Metrics

Financial Performance
Metric
AKA
AGEN
Price
$10.34
$4.64
Analyst Decision
Strong Buy
Buy
Analyst Count
3
2
Target Price
$24.33
$14.50
AVG Volume (30 Days)
2.6K
909.4K
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
100.00
EPS
N/A
N/A
Revenue
$600,208,000.00
$42,877,086.00
Revenue This Year
$6.14
$107.63
Revenue Next Year
$4.89
N/A
P/E Ratio
N/A
$8.89
Revenue Growth
4.44
89.95
52 Week Low
$7.00
$1.96
52 Week High
$16.38
$7.34

Technical Indicators

Market Signals
Indicator
AKA
AGEN
Relative Strength Index (RSI) 52.87 64.66
Support Level $8.94 $3.92
Resistance Level $10.53 $5.20
Average True Range (ATR) 0.54 0.37
MACD 0.10 0.11
Stochastic Oscillator 46.31 76.55

Price Performance

Historical Comparison
AKA
AGEN

About AKA a.k.a. Brands Holding Corp.

a.k.a. Brands Holding Corp is a portfolio of fashion brands, including Princess Polly, Culture Kings, Petal & Pup, and mnml. Through these brands, the company reaches next-generation consumers who seek fashion inspiration on social media and mainly shop online. The portfolio consists of two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company generates the majority of its revenue from the United States.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: